Aug 06, 2019 7:00am EDT Can-Fite to Treat Advanced Liver Cancer Patients with Namodenoson Under Compassionate Use Setting in Israel
Aug 01, 2019 8:45am EDT Can-Fite Signs Agreement with Kyongbo Pharm for the Distribution in South Korea of Piclidenoson in the Treatment of Psoriasis
Jun 04, 2019 7:00am EDT Can-Fite Participating in One-on-One Partnering Meetings at the BIO International Convention on June 3-6, 2019
Jun 03, 2019 7:00am EDT Findings from Can-Fite’s Phase II Liver Cancer Study were Presented at ASCO Annual Meeting Late-Breaking Session
May 29, 2019 7:00am EDT Can-Fite Reports First Quarter 2019 Financial Results & Provides Clinical Update
May 23, 2019 7:00am EDT The Anti-NASH Effect of Namodenoson will be Presented at the International Conference on Fatty Liver in Berlin
May 20, 2019 7:00am EDT Can-Fite’s Phase II Liver Cancer Data Selected for Presentation at a Leading Liver Cancer Scientific Forum (ILCA)
May 06, 2019 7:00am EDT Can-Fite Announces Preparation for End-of-Phase II Meeting with FDA to Initiate the Phase III Liver Cancer Study for Namodenoson
